US Federal 2025-2026 Regular Session

US Federal House Bill HB6789

Introduced
12/17/25  

Caption

Federal Prisons Naloxone Access Act of 2025

Impact

By enforcing the availability of these lifesaving medications, HB6789 seeks to reduce the incidence of overdose deaths within federal prisons. The bill requires that incarcerated individuals have access to opioid antagonists and mandates annual training for prison personnel and inmates on how to recognize overdose symptoms and properly administer these medications. This initiative not only aims to improve health outcomes for inmates but also serves as a proactive approach to public health by ensuring that people in correctional facilities are equipped to respond effectively to medical emergencies.

Summary

House Bill 6789, also known as the Federal Prisons Naloxone Access Act of 2025, aims to address the opioid crisis by mandating the availability of opioid antagonists, specifically naloxone, at federal correctional facilities. This bill recognizes the growing need for overdose prevention measures within these institutions, where individuals may be at heightened risk of opioid overdoses. The legislation stipulates that each facility must maintain a sufficient number of opioid antagonist kits in various locations such as medical units, breakrooms, and common areas to ensure quick access during emergencies.

Contention

There may be potential points of contention surrounding this bill, particularly in terms of its implementation and the allocation of necessary resources. The legislation authorizes appropriations for training and procurement of opioid antagonist kits, but it may face scrutiny over budget constraints and logistical challenges in making these medications available throughout all federal correctional facilities. Additionally, ensuring that the training provided is effective and comprehensive could be a challenge, raising questions about the adequacy of funding and support for such programs in the long run.

Companion Bills

No companion bills found.

Previously Filed As

US SB3588

School Access to Naloxone Act of 2026

US SB698

Federal Prisons Accountability Act of 2025

US HB4355

Federal Prisons Accountability Act of 2025

US LB5

Provide immunity for administration of naloxone or other federally approved opioid antagonists

US HB1046

Marc Fischer Memorial Act Marc Fischer Memorial Interdiction of Fentanyl in Postal Mail at Federal Prisons Act

US S1551

Establishing a naloxone purchase trust fund

US HB3326

METRA-NALOXONE REQUIREMENT

US HB3612

End For-Profit Prisons Act of 2025

US H2535

Establishing a Naloxone Purchase Trust fund

US H4730

Establishing a Naloxone Purchase Trust fund

Similar Bills

HI HB310

Relating To Opioid Antagonists.

HI HB310

Relating To Opioid Antagonists.

TX HB4783

Relating to a report on governmental opioid antagonist programs to reverse and prevent opioid overdoses.

AZ HB2697

expired opioid antagonists; use

MT SB503

Allow use of expired opioid antagonists

TX HB1103

Relating to measures to prevent and respond to opioid-related drug overdoses, including policies and training regarding the use of opioid antagonists, at student residences on campuses of public institutions of higher education; providing immunity.

MI SB0401

Health: pharmaceuticals; co-prescribing of naloxone with opioid drugs; require. Amends sec. 17744b of 1978 PA 368 (MCL 333.17744b).

TX SB556

Relating to measures to prevent and respond to opioid-related drug overdoses, including policies and training regarding the use of opioid antagonists, at student residences on campuses of public institutions of higher education; providing immunity.